Company Overview and News

 
Billion-Dollar Unicorns: Will A Sales Strategy Change Help Cloudera?

2018-04-17 seekingalpha
Earlier this year, analysts expected Cloudera to die a slow death, driven by rising competition from established players.
Upvote Downvote

 
The MnM Portfolio, Mar 2018 - A Leaner And Meaner Portfolio

2018-04-11 seekingalpha
This month’s article marks the thirty-seventh installment in my on-going series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
Upvote Downvote

 
EMR / Emerson Electric Co. 8-K (Current Report)

2018-04-03 sec.gov
Document UNITED STATES
Upvote Downvote

 
Parker-Hannifin: Over A Century Of Success

2018-03-24 seekingalpha
Parker has done a good job of carving out its distributor network and building customer relationships in the aerospace industry.
Upvote Downvote

 
EMR / Emerson Electric Co. 8-K (Current Report)

2018-03-15 sec.gov
Document UNITED STATES
Upvote Downvote

1
Retirement Strategy: Is Buying The Dip Dead?

2018-03-03 seekingalpha
"Buy the dip" has been the rallying cry for DGIers for over a decade. Unfortunately, greater volatility might be tossing a monkey wrench into that approach. Given the market's action over the last 6 weeks or so, it appears that the volatility might give us more dips than we can afford!
Upvote Downvote

 
Retirement Strategy: If You Have The Time, Why Wait To Have Your Money Work For You?

2018-03-01 seekingalpha
If you have decades before you leave the rat race, what should you do with that pile of cash you've saved?
Upvote Downvote

 
Retirement Strategy: What The Heck Are You Waiting For?

2018-02-24 seekingalpha
I've written enough about folks close to or already in retirement. Now I am reaching out to those who have not even started investing for a more secure financial future.
Upvote Downvote

 
How Far Could Rockwell Automation Fall?

2018-02-22 seekingalpha
My research has mostly focused on finding the best way to profit from cyclical stocks near the bottom of the economic cycle.
Upvote Downvote

 
Retirement Strategy: Did We Have A Correction, Or Was I Hallucinating?

2018-02-21 seekingalpha
The facts speak for themselves, and we did have a rather harsh but brief correction. Let's take a look at it:
Upvote Downvote

 
Fortive: I Missed The Party

2018-02-20 seekingalpha
But analysis is by no means impossible, and a low valuation at spin-off and subsequent earnings surprises should be baked into expectations by now.
Upvote Downvote

2
Retirement Strategy: Inflation Is A Scourge On Retirees' Well-Being

2018-02-17 seekingalpha
Rarely do I write an article such as the one I am penning right now, but I think it is important to put inflation in perspective for regular folks, along with my opinion.
Upvote Downvote

1
Top Analyst Upgrades and Downgrades: AMAG, Baidu, Cisco, GE, Honeywell, 3M, Salesforce, SunPower, UTC and More

2018-02-15 247wallst
This week has been a wild ride, but it has been a week full of recovery in stocks versus last week’s panic selling with broken market efficiencies. The bull market is now just three weeks shy of being nine years old, and the one trend that has served investors huge rewards for over five years now has been to buy the pullbacks. Investors still have to decide how they want to be positioned for 2018 and beyond.
Upvote Downvote

1
Top Analyst Upgrades and Downgrades: Avis Budget, Blue Apron, Chipotle, Domino’s, Northrop Grumman, Pepsi, Rio Tinto, T-Mobile, Valero and More

2018-02-14 247wallst
Volatility is back, with another day of gains rapidly turning into strong selling pressure with consumer prices indicating hotter than expected inflation. Some signals were already pointing to this, but efficient market theory has been dead for quite some time. The bull market is now just three weeks shy of being nine years old, and the one trend that has served investors huge rewards for over five years now has been to buy the pullbacks.
Upvote Downvote

 
EMR / Emerson Electric Co. / STATE STREET CORP - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING EMERSON ELECTRIC CO. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 291011104 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHAL
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 291011104